)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Bora Pharmaceuticals
Bora Pharmaceuticals (6472) investor relations material
Bora Pharmaceuticals Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary13 Aug, 2026
Executive summary
Achieved double- and triple-digit quarter-over-quarter growth across key metrics in Q2 2026, following a Q1 pullback, with strong recovery driven by demand and operational leverage.
Revenues reached NT$5,889 million in Q2 2026, up 47% quarter-over-quarter and 21% year-over-year, with gross profits at NT$2,430 million (69% growth) and EPS of NT$4.36 (1,976% growth quarter-over-quarter).
Net income before tax was NT$812 million, a 269% quarter-over-quarter increase, and net income rose from NT$32 million in Q1 to NT$597 million in Q2.
Expanded U.S. footprint with 11 manufacturing sites and a major acquisition of the Rockville, Maryland biologics facility.
Completed the acquisition of Weider Global Nutrition, LLC in May 2026, expanding the health and wellness product portfolio.
Financial highlights
CDMO business revenue was NT$2,116 million, up 40.2% quarter-over-quarter; pharma sales revenue was NT$2,934 million, up 30.4%.
Record high 12-month rolling backlog of US$317 million and newly signed contracts totaling US$378 million.
Operating profits nearly doubled to NT$986 million from NT$400 million quarter-over-quarter; operating margin reached 17%.
Sunway Biotech, now 14% of total revenues, contributed significantly after acquiring Weider Global Nutrition.
Cash and cash equivalents increased to NT$8,431 million as of June 30, 2026.
Outlook and guidance
Strong visibility for the second half of 2026 and into 2027, with record backlog and continued demand for CDMO and specialty pharma.
Rockville facility to contribute revenue in Q3 2026, with 13 batches already committed for the back half of 2026.
Sunway Biotech expected to realize further synergies and growth from Weider acquisition in H2 2026.
Ongoing investments in R&D and manufacturing capabilities, including CapEx at Maple Grove and Maryland.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Bora Pharmaceuticals
- Revenue and profit fell, but strong backlog and acquisitions support future growth.6472
Q1 2026 - Record CDMO growth, biologics expansion, and specialty pharma drive strong 2026 outlook.6472Life Sciences Virtual Investor Forum
- 2025 featured strong revenue and profit growth, resilient cash flow, and global expansion.6472Q4 2025
- Record global growth, capacity investments, and specialty expansion drive strong 2025 results.647244th Annual J.P. Morgan Healthcare Conference
- Record CDMO and specialty pharma growth led to strong revenue and margin gains in Q3'25.6472Q3 2025
- Strong revenue and profit growth from CDMO and specialty pharma, with margin recovery ahead.6472Q2 2025
- Rapid growth, major acquisitions, and innovative CNS launches drive expansion and future outlook.6472Bora Pharmaceuticals Co., LTD. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025
- Record CDMO and specialty pharma growth, equity swap gain, and higher margins in Q1 2025.6472Q1 2025
- Record 2024 growth from U.S. acquisitions and CDMO expansion sets up for stronger 2025.6472Q4 2024
Next Bora Pharmaceuticals earnings date
Q3 202612 Nov, 2026
Bora Pharmaceuticals
Next Bora Pharmaceuticals earnings date
Q3 202612 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Bora Pharmaceuticals Co., Ltd. is active in the pharmaceutical industry, focusing on manufacturing and selling generic, brand, and over-the-counter drugs globally. The company spans the entire pharmaceutical supply chain from research and development to sales and distribution, offering services including contract development and manufacturing, consumer healthcare & OTC, and prescription drugs. Bora's facilities are certified by USFDA, MHRA, and PIC/S, ensuring the production of pharmaceuticals to the highest medical standards for distribution to over 100 countries worldwide. The company is headquartered in Taipei City, Taiwan, and its shares are listed on the Taiwan Stock Exchange.